Searchable abstracts of presentations at key conferences in endocrinology

ea0037gp.19.06 | Pituitary–Acromegaly | ECE2015

Criteria for disease control in acromegaly under SSA treatment: mean GH profile or GH random?

Prencipe Nunzia , Bona Chiara , Karamouzis Joannis , Berton Alessandro Maria , Di Giacomo Stellina Valentina , Guaraldi Federica , Ghigo Ezio , Grottoli Silvia

Acromegaly is due to increased GH secretion usually sustained by a GH-secreting pituitary adenoma. Somatostatin analogues (SSA) can control GH hypersecretion in 60% of patients and tumor volume in 30%. The disease control is, in turn, associated with lower mortality and therefore to verify the optimal control of the disease activity is of critical importance to adapt the dose and the choice of alternative treatment. The criteria for optimized disease control had been assumed a...

ea0070aep609 | Pituitary and Neuroendocrinology | ECE2020

Biliary stone disease in acromegaly under somatostatinanalogues: A longterm safety study

Prencipe Nunzia , Cuboni Daniela , Bona Chiara , Maria Berton Alessandro , Parasiliti Caprino Mirko , Fenoglio Luigi , Gasco Valentina , Ghigo Ezio , Grottoli Silvia

Introduction: Somatostatin analogues (SSA) are one of the main effective drug used in acromegaly. Sludge and/or cholelithiasis development represents oneof the more common side effect. The aim of the study was to analyze the frequency of biliary adverse events (BAE) and possible predictive factors, to propose a work-up strategy for their management.Method: This is a single centre, longitudinalretrospective study; we enrolled 91 acromegaly patients during...

ea0026p710 | Diabetes (epidemiology, pathophysiology) | ECE2011

Continuous glucose monitoring enhances the diagnostic value of mixed meal test in reactive hypoglycemia

Olivetti Ilaria , Grassi Giorgio , Lambertenghi Veronica , Tomelini Michela , Gigliardi Valentina Ramella , Gramaglia Elena , Ghigo Ezio , Broglio Fabio

Background: Clinical reactive hypoglycemic events are defined as the coexistence of plasma glucose <60 mg/dl and autonomic and/or neuroglycopenic symptoms occurring in fed conditions. The diagnosis is based on tests aiming to simulate the causative triggers (i.e. mixed meal test). In clinical practice, however, a high percentage of symptomatic patients results negative to such diagnostic approach, leading to the impression of an inadequate sensitivity of this diagnostic to...

ea0022p360 | Diabetes | ECE2010

Obestatin and ghrelin inhibit apoptosis of human pancreatic islet endothelial cells in high glucose culture

Favaro Enrica , Zanone Maria Maddalena , Miceli Ilaria , Settanni Fabio , Camussi Giovanni , Perin Paolo Cavallo , Ghigo Ezio , Granata Riccarda

Pancreatic islet microendothelium exhibits unique structural and functional features, in an interdependent physical and functional relationship with the neighbouring β-cells. Glucose toxicity is not solely restricted to β-cells, but affects also survival, proliferation of human pancreatic islet endothelial cells, thus possibly contributing to β-cell function impairment and β-cell loss. It has been previously demonstrated that the ghrelin gene derived peptid...

ea0022p601 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Basal and stimulated GH secretion in Cushing's syndrome: effects of ghrelin and GHRH+arginine

Picu Andreea , Marinazzo Elisa , Prodam Flavia , Broglio Fabio , Belcastro Sara , Aimaretti Gianluca , Giordano Roberta , Ghigo Ezio , Arvat Emanuela

GH secretion is usually impaired in active Cushing’s syndrome (CS), due to concomitant mechanisms, including diminished GHRH and/or increased somatostatin release and impaired pituitary somatotrope responsiveness. Differently, IGF1 levels not parallel GH insufficiency in CS, being reported reduced, normal or increased. Both ghrelin and GHRH+arginine (ARG) are powerful GH secretagogues, influenced by age and/or BMI. In 27 CS (42.7±2.9 years, 28.8±0.9 kg/m2</...

ea0020oc4.5 | Acromegaly/IGF1/Type 2 Diabetes | ECE2009

Regulation of obestatin levels during unacylated ghrelin infusions in normal and type 2 diabetic patients

St-Pierre David H , Settanni Fabio , Olivetti Ilaria , Gramaglia Elena , Benso Andrea , Riganti Fabrizio , Ghigo Ezio , Broglio Fabio

Background: Obestatin, a ghrelin gene product was recently isolated but important questions remain regarding its regulation and its physiological effects. The aim of the present study was to evaluate the effect of unacylated ghrelin (UAG) on obestatin levels in normal subjects and patients with type 2 diabetes (T2D).Methods: Five normal subjects and 5 T2D patients were included in this study. Unacylated ghrelin (3 μg/kg per hour) or saline were cont...

ea0020p117 | Thyroid | ECE2009

Subjective and objective sleep evaluation in patients with hypo- and hyper-thyroidism

Riganti Fabrizio , Noi Fabiana Di , Seardo Maria Angela , Gramaglia Elena , Bonelli Nadia , Rossetto Ruth , Ghigo Ezio , Broglio Fabio

Hyper- and hypo-thyroidism are considered as clinical conditions of sleep alterations. At present, however, these clinical reports have never been confirmed by studies providing a structured description of subjective and objective sleep quantity and quality. To this aim, we enrolled 15 patients with naïve overt hyperthyroidism (HYPER), 9 with naïve overt primary hypothyroidism (HYPO) and 15 healthy age-, sex- and BMI-matched control subjects (CS). Clinical conditions...

ea0020p439 | Obesity and Metabolism | ECE2009

The evaluation of metabolic effects following ghrelin and salbutamol administration

Benso Andrea , St-Pierre David H , Gramaglia Elena , Riganti Fabrizio , Lucatello Barbara , Olivetti Ilaria , Ghigo Ezio , Broglio Fabio

Background: The activation of the GHS-R1a receptor by acylated ghrelin (AG) or by synthetic GH secretagogues (GHS), potently stimulates GH release and mediates other neuroendocrine/metabolic effects. Beta-adrenergic receptor agonists negatively influence GH secretion and other metabolic functions. The GH response to AG and GHS is refractory to the inhibitory effect of β2-adrenoceptors activation but no other report has evaluated the interactions between AG and salbutamol ...

ea0016p512 | Obesity | ECE2008

No feedback inhibition of obestatin during acylated ghrelin infusion in humans

Lucatello Barbara , St-Pierre David H. , Settanni Fabio , Olivetti Ilaria , Benso Andrea , Granata Riccarda , Ghigo Ezio , Broglio Fabio

Background: Obestatin is a 27 aa peptide derived from the ghrelin gene. Obestatin was first described to exert anorexigenic effects by decreasing gastric motility in rodent models, however these results have been debated and there is presently only small information regarding its activity and its regulation in humans. Furthermore, its interactions with acylated ghrelin (AG), derived from the same gene, have not been evaluated. Therefore, in these preliminary data, we sought to...

ea0016p532 | Obesity | ECE2008

Diabetogenic effects of a continuous infusion of acylated ghrelin in normal and type 2 diabetic patients

St-Pierre David H , Olivetti Ilaria , Pomero Elisa , Gramaglia Elena , Riganti Fabrizio , Benso Andrea , Ghigo Ezio , Broglio Fabio

Background: Previous studies have shown that acylated ghrelin (AG) modulates insulin secretion and glucose disposal in vitro and after acute administration in humans. The aim of the present study was to evaluate postprandial glucose and insulin response following AG infusion in normal subjects and patients with type 2 diabetes.Methods: Six normal subjects and 3 patients with type 2 diabetes were included in this study. AG (1 μg/kg per h) or s...